Precision Picks New CEO To Tackle Gene Editing’s Commercial Challenges
Michael Amoroso’s Yescarta Experience Valued
Precision is looking ahead to market access challenges for its off-the-shelf CAR-T and in vivo gene-editing therapies.
You may also be interested in...
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.
Animal studies have shown that AAV viral vectors can integrate into animal cell DNA – but whether that causes cancer, or could happen in humans, remains uncertain.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.